Helsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair®, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis
Lugano, Switzerland / Raleigh, N.C., USA (ots) - Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. ...
mehr